Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3237518 | 0.86 | CYP46A1 (0.46) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3242158 | 0.84 | CYP46A1 (0.42) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3236551 | 0.83 | CYP46A1 (0.40) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3232554 | 0.80 | MEN1 (0.41) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3232447 | 0.80 | L3MBTL1 (0.40) | CYP46A1SMN1; SMN2SPRMGLLCYP2C9 | |
| SCHEMBL3823682 | 0.79 | ALDH1A1 (0.39) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3240308 | 0.79 | CYP46A1 (0.41) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3240073 | 0.78 | CYP46A1 (0.48) | CYP46A1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL3247535 | 0.77 | GAA (0.43) | CYP46A1SMN1; SMN2 | |
| SCHEMBL8018991 | 0.76 | L3MBTL1 (0.41) | CYP46A1SMN1; SMN2SPRMGLLCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | disclosed |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | disclosed |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-04-22 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
| WO-2009131952-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING THIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | CYP46A1 215/4885GRIN2D 4188/4885GRIN3B 3701/4885 |
| US-20100099677-A1 | Compounds, Compositions and Methods Comprising Thiazole Derivatives | CFTR, PKD1, PKD2 | CYP46A1 983/4885GRIN2D 4407/4885GRIN3B 4339/4885 |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | CYP46A1 215/4885GRIN2D 4188/4885GRIN3B 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.